Saba Capital Management, L.P. Sells 15,400 Shares of Abrdn Life Sciences Investors (NYSE:HQL) Stock

Posted by Casey Walker on Apr 17th, 2025

Abrdn Life Sciences Investors (NYSE:HQL – Get Free Report) major shareholder Saba Capital Management, L.P. sold 15,400 shares of the business’s stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $11.67, for a total value of $179,718.00. Following the sale, the insider now directly owns 3,078,916 shares of the company’s stock, valued at $35,930,949.72. This represents a 0.50 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Saba Capital Management, L.P. also recently made the following trade(s):

On Thursday, April 10th, Saba Capital Management, L.P. sold 30,156 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $11.14, for a total value of $335,937.84.
On Friday, April 4th, Saba Capital Management, L.P. sold 6,889 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $11.57, for a total transaction of $79,705.73.
On Wednesday, April 2nd, Saba Capital Management, L.P. sold 29,102 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $12.28, for a total transaction of $357,372.56.
On Monday, March 31st, Saba Capital Management, L.P. sold 48,623 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $12.58, for a total transaction of $611,677.34.
On Thursday, March 27th, Saba Capital Management, L.P. sold 32,922 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.01, for a total value of $428,315.22.
On Wednesday, February 26th, Saba Capital Management, L.P. sold 200 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $13.62, for a total value of $2,724.00.
On Wednesday, February 12th, Saba Capital Management, L.P. sold 36,536 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $13.75, for a total value of $502,370.00.
On Monday, February 10th, Saba Capital Management, L.P. sold 42,987 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.95, for a total value of $599,668.65.
On Monday, February 3rd, Saba Capital Management, L.P. sold 1,846 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $14.03, for a total transaction of $25,899.38.
On Friday, January 31st, Saba Capital Management, L.P. sold 15,143 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $14.27, for a total transaction of $216,090.61.

Abrdn Life Sciences Investors Trading Down 0.7 %

Shares of NYSE HQL opened at $11.68 on Thursday. Abrdn Life Sciences Investors has a 52-week low of $10.55 and a 52-week high of $15.90. The firm’s fifty day moving average is $12.91 and its two-hundred day moving average is $13.76.

Abrdn Life Sciences Investors Cuts Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, March 31st. Stockholders of record on Friday, February 21st were issued a $0.47 dividend. The ex-dividend date of this dividend was Friday, February 21st. This represents a $1.88 annualized dividend and a dividend yield of 16.10%.

Institutional Investors Weigh In On Abrdn Life Sciences Investors

A number of hedge funds have recently made changes to their positions in the company. Sanctuary Advisors LLC raised its holdings in shares of Abrdn Life Sciences Investors by 11.4% during the 3rd quarter. Sanctuary Advisors LLC now owns 13,256 shares of the company’s stock worth $183,000 after acquiring an additional 1,355 shares in the last quarter. Janney Montgomery Scott LLC increased its position in Abrdn Life Sciences Investors by 7.3% in the fourth quarter. Janney Montgomery Scott LLC now owns 91,398 shares of the company’s stock worth $1,199,000 after purchasing an additional 6,200 shares during the last quarter. Kingswood Wealth Advisors LLC purchased a new stake in Abrdn Life Sciences Investors during the fourth quarter valued at $160,000. Absolute Investment Advisers LLC bought a new position in Abrdn Life Sciences Investors during the fourth quarter valued at $5,242,000. Finally, Wolverine Asset Management LLC purchased a new position in shares of Abrdn Life Sciences Investors in the 4th quarter worth $1,594,000. 32.21% of the stock is currently owned by hedge funds and other institutional investors.

About Abrdn Life Sciences Investors

(Get Free Report)

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.